Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.42 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | BTK | Q06187 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | STS | P08842 | 1/20 | 0.37 |
| ▸ | SUV39H2 | Q9H5I1 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | CFTR | P13569 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.36 |
| ▸ | PDE4A | P27815 | 1/20 | 0.36 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13555270 | 0.85 | CYP2C9 (0.50) | CYP2C9CYP3A4CYP2D6CYP1A2CYP2C8 | |
| SCHEMBL13555232 | 0.85 | CYP2C9 (0.49) | CYP2C9CYP3A4CYP2D6CYP1A2CYP2C8 | |
| SCHEMBL13554652 | 0.84 | CYP2C9 (0.48) | CYP2C9CYP3A4CYP2D6CYP1A2CYP2C8 | |
| SCHEMBL8530418 | 0.82 | CYP2C9 (0.69) | CYP2C9CYP3A4CYP2D6CYP1A2CYP2C8 | |
| SCHEMBL14122904 | 0.81 | CYP2C9 (0.48) | CYP2C9CYP3A4CYP2D6CYP1A2CYP2C8 | |
| SCHEMBL12787815 | 0.81 | CYP2C9 (0.58) | CYP2C9CYP3A4CYP2D6CYP1A2CYP2C8 | |
| SCHEMBL2628965 | 0.80 | CYP2C9 (0.55) | CYP2C9CYP3A4CYP2D6CYP1A2CYP2C8 | |
| SCHEMBL14122511 | 0.76 | CYP2C9 (0.52) | CYP2C9CYP3A4CYP2D6CYP1A2CYP2C8 | |
| SCHEMBL13899823 | 0.76 | CYP2C9 (0.52) | CYP2C9CYP3A4CYP2D6CYP1A2CYP2C8 | |
| SCHEMBL15591947 | 0.75 | PTAFR (0.46) | CYP2C9CYP3A4CYP2D6CYP1A2CYP2C8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160082102-A1 | BIFUNCTIONAL MOLECULES WITH ANTIBODY-RECRUITING AND ENTRY INHIBITORY ACTIVITY AGAINST THE HUMAN IMMUNODEFICIENCY VIRUS | UNIV YALE (US) | 2016-03-24 | — | — | US | disclosed |
| US-9181224-B2 | Bifunctional molecules with antibody-recruiting and entry inhibitory activity against the human immunodeficiency virus | YALE UNIVERSITY (US) | 2015-11-10 | — | — | US | disclosed |
| US-20120269766-A1 | BIFUNCTIONAL MOLECULES WITH ANTIBODY-RECRUITING AND ENTRY INHIBITORY ACTIVITY AGAINST THE HUMAN IMMUNODEFICIENCY VIRUS | YALE UNIVERSITY (US) | 2012-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120269766-A1 | BIFUNCTIONAL MOLECULES WITH ANTIBODY-RECRUITING AND ENTRY INHIBITORY ACTIVITY AGAINST THE HUMAN IMMUNODEFICIENCY VIRUS | CD4, HAVCR2, CD2BP2 | CYP2C9 4672/4885CYP3A4 3518/4885CYP2D6 2910/4885 |
| US-20160082102-A1 | BIFUNCTIONAL MOLECULES WITH ANTIBODY-RECRUITING AND ENTRY INHIBITORY ACTIVITY AGAINST THE HUMAN IMMUNODEFICIENCY VIRUS | CD4, HAVCR2, CD2 | CYP2C9 4639/4885CYP3A4 3336/4885CYP2D6 2709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.